



Accreditation Statement:



In support of improving patient care, American Academy of Addiction Psychiatry is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Target Audience Statement

This intensive online course is designed for physicians and other health care professionals who have a foundation in prescribing medication for patients with substance use disorders, including those with co-occurring psychiatric conditions, but would like a deeper understanding of these pharmacotherapies. Credit for this activity is designated for learners in the following ways:

Physician Designation Statement

American Academy of Addiction Psychiatry designates this enduring for a maximum of 13.75 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Health Professionals Designation Statement

Participants will receive a Certificate of Attendance stating this program is designated for 13.75 *AMA PRA Category 1 Credits*™. This credit is accepted by the AANP and the AAPA.

Educational Objectives:

Learners who attend this activity will receive a more in-depth educational experience in the pharmacotherapy of substance use disorders and co-occurring conditions and after participating in this course, learners should be able to:

- Discuss use of methadone, buprenorphine and injectable OUD pharmacotherapies in clinical practice for the treatment of opioid use disorders.
- Evaluate medication treatments for alcohol use disorders.
- Discuss use of varenicline, bupropion, and nicotine replacement therapy (NRT) for treatment of nicotine use disorders.
- Identify treatment issues related to stimulant use disorder pharmacotherapy.
- Evaluate new evidence for medication treatments for cannabis use disorder.
- Discuss new evidence for medications for the treatment of sedative-hypnotic use disorder.

- Review evidence-based non-pharmacological treatments such as brain stimulation for treatment of patients with primary and co-occurring substance use disorders.

Faculty:

- John Mariani, MD
- Kevin Sevarino, MD, PhD
- Richard Rosenthal, MD
- Jill Williams, MD
- Kevin Gray, MD
- Larissa Mooney, MD
- Christina Brezing, MD
- Diana Martinez, MD

Topics:

- Alcohol Use Disorder Pharmacotherapy: *From Detox to Relapse Prevention; Medication Treatments for AUD*
- Cannabis Use Disorder Pharmacotherapy: *Promising Approaches on the Horizon*
- Nicotine Use Disorder Pharmacotherapy: *An Underused Arsenal: Varenicline, Bupropion, and NRT*
- Opioid Use Disorder Pharmacotherapy: *Oral OUD Pharmacotherapy and Pain Management*
- Opioid Use Disorder Pharmacotherapy: *Injectable OUD Pharmacotherapy*
- Sedative-Hypnotic Use Disorder Pharmacotherapy: *Inpatient and Outpatient Medication Approaches*
- Stimulant Use Disorder Pharmacotherapy: *Clinical Effects and Treatment Issues*
- Brain Stimulation: *Brain Stimulation for Addiction: Present & Future*

Disclosure to Learners:

In accordance with the disclosure policy of the American Academy of Addiction Psychiatry, as well as standards set forth by JAC policies and guidelines and the ACCME, the JAC expects accredited providers to present learners with unbiased, independent, and objective information in all activities. Accredited providers must be in compliance with the Standards for Integrity and Independence in Accredited Continuing Education. Therefore, Presenter(s), Planner(s), Reviewer(s), and all others involved in the planning or content development of this activity were required to disclose all financial relationships within the past 24 months.

For this activity, the following relevant financial relationships were disclosed:

Kevin Gray, MD	Aelis Farma Achieve Life Sciences Indivior	Research Support Consultant Consultant
----------------	--	--

All disclosures have been reviewed and all relevant financial relationships have been mitigated.

All other individuals involved in the planning and presentation of this activity have no relevant financial relationships with ineligible companies to disclose.

All speakers have been advised that any recommendations involving clinical medicine must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in the presentation must conform to the generally accepted standards of experimental design, data collection, and analysis. Faculty have also been advised that they must not actively promote or sell products or services that serve their professional or financial interests during accredited education.

Breakdown of Credit:

On-Demand Recorded Lectures		CME Credits
75 Minutes	Opioid Use Disorder Pharmacotherapy <i>Oral OUD Pharmacotherapy and Pain Management</i>	1.25
93 Minutes	Opioid Use Disorder Pharmacotherapy <i>Injectable OUD Pharmacotherapy</i>	1.50
65 Minutes	Alcohol Use Disorder Pharmacotherapy <i>From Detox to Relapse Prevention; Medication Treatments for AUD</i>	1.00
56 Minutes	Nicotine Use Disorder Pharmacotherapy <i>An Underused Arsenal: Varenicline, Bupropion, and NRT</i>	1.00
63 Minutes	Sedative-Hypnotic Use Disorder Pharmacotherapy <i>Inpatient and Outpatient Medication Approaches</i>	1.00
46 Minutes	Stimulant Use Disorder Pharmacotherapy <i>Clinical Effects and Treatment Issues</i>	0.75
38 Minutes	Cannabis Use Disorder Pharmacotherapy <i>Promising Approaches on the Horizon</i>	0.75
46 Minutes	Brain Stimulation <i>Brain Stimulation for Addiction: Present & Future</i>	0.75
		8.00
Recorded Live Q&A Sessions		
46 Minutes	Opioid Use Disorder Pharmacotherapy <i>Oral OUD Pharmacotherapy and Pain Management</i> Kevin Sevarino, MD, PhD	0.75
41 Minutes	Opioid Use Disorder Pharmacotherapy <i>Injectable OUD Pharmacotherapy</i> John Mariani, MD	0.75
45 Minutes	Alcohol Use Disorder Pharmacotherapy <i>From Detox to Relapse Prevention; Medication Treatments for AUD</i> Richard Rosenthal, MD	0.75
43 Minutes	Nicotine Use Disorder Pharmacotherapy <i>An Underused Arsenal: Varenicline, Bupropion, and NRT</i> Jill Williams, MD	0.75
45 Minutes	Stimulant Use Disorder Pharmacotherapy <i>Clinical Effects and Treatment Issues</i> Larissa Mooney, MD – On-Demand Presenter	0.75
48 Minutes	Sedative-Hypnotic Use Disorder Pharmacotherapy <i>Inpatient and Outpatient Medication Approaches</i> Christina Brezing, MD	0.75
41 Minutes	Cannabis Use Disorder Pharmacotherapy <i>Promising Approaches on the Horizon</i> Kevin Gray, MD	0.75
36 Minutes	Brain Stimulation <i>Brain Stimulation for Addiction: Present & Future</i> Diana Martinez, MD	0.50

		5.75
--	--	-------------

Maximum Credit per Day	CME Credits
On-Demand	8.00
Recorded Live Q&As	5.75
Grand total 13.75 <i>AMA PRA Category 1 Credits™</i>	